GSTP1 Methylation Test May Help PSA Screening for Prostate Cancer
Author Information
Author(s): Wu T, Giovannucci E, Welge J, Mallick P, Tang W-Y, Ho S-M
Primary Institution: University of Cincinnati Medical Center
Hypothesis
Can GSTP1 promoter methylation in body fluids improve the specificity of prostate cancer detection compared to PSA screening?
Conclusion
The GSTP1 methylation test shows high specificity and may complement PSA screening for prostate cancer diagnosis.
Supporting Evidence
- The pooled specificity of GSTP1 methylation was 0.89, indicating high accuracy.
- The sensitivity of GSTP1 was found to be 0.52, which is modest compared to PSA.
- GSTP1 methylation testing can be performed using non-invasive body fluids like blood and urine.
- High specificity of GSTP1 methylation suggests it could reduce unnecessary biopsies.
- Meta-regression analyses showed no significant associations between sensitivity and age or sample type.
Takeaway
This study found that a test measuring a specific gene change in blood or urine can help doctors better identify prostate cancer, working alongside the usual PSA test.
Methodology
A meta-analysis of 22 studies assessing GSTP1 methylation in various body fluids for prostate cancer detection.
Potential Biases
Potential selection bias due to the classification of controls and exclusion of healthy controls.
Limitations
Variability in sample collection timing and methylation methods across studies may affect results.
Participant Demographics
Participants were adults aged 40–74 years.
Statistical Information
P-Value
<0.001
Confidence Interval
0.80–0.95
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website